DGIdb - COLCHICINE Drug Record

COLCHICINE chembl:CHEMBL107 ApprovedAntineoplasticImmunotherapy

Alternate Names:

GLOPERBA
COLCHICINE
MITIGARE
NSC-757
COLCRYS
BENZO(A)HEPTALEN-9(5H)-ONE
COLCHICINA
CONDYLON
N-(1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDROBENZO[A]HEPTALEN-7-YL)ACETAMIDE
COLSALOID
COLCHICIN
COLCHICINUM
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
COLGOUT
N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
N-ACETYLTRIMETHYLCOLCHICINIC ACID METHYL ETHER
drugbank:01394
chembl:CHEMBL87
chemidplus:64-86-8
rxcui:2683
pubchem.compound:6167
chembl:CHEMBL107

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of gout
Drug Class	gout suppressants
Year of Approval	approved before 1982
Drug Categories	tubulin modulators
Drug Categories	therapeutic uses
Drug Categories	preparations with no effect on uric acid metabolism
Drug Categories	pharmacologic actions
Drug Categories	p-glycoprotein/abcb1 substrates
Drug Categories	p-glycoprotein/abcb1 inhibitors
Drug Categories	musculo-skeletal system
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	mitosis modulators
Drug Categories	heterocyclic compounds
Drug Categories	gout suppressants
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a inhibitors
Drug Categories	cytochrome p-450 cyp3a inducers
Drug Categories	cytochrome p-450 cyp2e1 inducers
Drug Categories	cytochrome p-450 cyp2c9 inhibitors
Drug Categories	cytochrome p-450 cyp2c9 inducers
Drug Categories	cytochrome p-450 cyp2c8 inhibitors
Drug Categories	cytochrome p-450 cyp2c8 inducers
Drug Categories	cytochrome p-450 cyp2b6 inhibitors
Drug Categories	combined inhibitors of cyp3a4 and p-glycoprotein
Drug Categories	chemical actions and uses
Drug Categories	antirheumatic agents
Drug Categories	antineoplastic agents
Drug Categories	antimitotic agents
Drug Categories	antigout preparations
Drug Categories	alkaloids
Drug Groups	approved
Drug Type	small molecule
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein inducers
Drug Categories	immunosuppressive agents
Drug Categories	drugs that are mainly renally excreted
Drug Categories	cytochrome p-450 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp2e1 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2b6 inhibitors (strength unknown)
Drug Categories	agents causing muscle toxicity

(6 More Sources)

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem
Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem
Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem
Zhang X et al., 2015, Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors., Eur J Med Chem
Wang XF et al., 2014, Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site., J Med Chem
Minegishi H et al., 2015, Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods., J Med Chem
Canela MD et al., 2014, Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach., J Med Chem
Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Mader et al., 2004, Dual mode of signalling of the axotomy reaction: retrograde electric stimulation or block of retrograde transport differently mimic the reaction of motoneurons to nerve transection in the rat brainstem., J. Neurotrauma
Pozas et al., 1999, Fra-1 immunoreactivity in the rat brain during normal postnatal development and after injury in adulthood., Neurosci. Res.
Yalcıntepe S et al., 2016, The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients., Eur J Drug Metab Pharmacokinet
Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics
Acharya et al., 2009, Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity., Biochemistry
Finkelstein et al., 2010, Colchicine poisoning: the dark side of an ancient drug., Clin Toxicol (Phila)
Cerquaglia et al., 2005, Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update., Curr Drug Targets Inflamm Allergy
Li et al., 2010, Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin., J Mass Spectrom
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Yee et al., 2005, Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies., Clin. Cancer Res.
Lu Y et al., 2012, An overview of tubulin inhibitors that interact with the colchicine binding site., Pharm Res
Dalbeth N et al., 2014, Mechanism of action of colchicine in the treatment of gout., Clin Ther
Kasturi et al., 1984, Colchicine inhibition of insulin induction of stearoyl-CoA desaturase and fatty acid synthetase in cultured avian liver explants., Arch. Biochem. Biophys.
Antoniou et al., 2004, Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP)., Sarcoidosis Vasc Diffuse Lung Dis
Geddes et al., 1994, Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and MAP2., Brain Res.
Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.
Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
Danielsen et al., 1983, Biosynthesis of intestinal microvillar proteins. Role of the Golgi complex and microtubules., Biochem. J.
Huang et al., 2005, Disruption of microtubules ablates the specificity of insulin signaling to GLUT4 translocation in 3T3-L1 adipocytes., J. Biol. Chem.
Stromskaya et al., 1998, Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines., Br. J. Cancer
Dvorák et al., 2007, Expression, protein stability and transcriptional activity of retinoic acid receptors are affected by microtubules interfering agents and all-trans-retinoic acid in primary rat hepatocytes., Mol. Cell. Endocrinol.
Cronstein et al., 1995, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils., J. Clin. Invest.
Torre et al., Effects of interleukin-8 on suppression of human lymphocyte polarization and migration by anti-LFA-1 antibody., Eur. Cytokine Netw.
Sandrock et al., 1995, ARIA is concentrated in nerve terminals at neuromuscular junctions and at other synapses., J. Neurosci.
Lakkakorpi et al., 1997, Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading., Exp. Cell Res.

COLCHICINE GLRA2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:
COLCHICINE BRD4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
COLCHICINE GLRA1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? False

Publications:

COLCHICINE TUBA3E

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB8

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB2A

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name colchicine,Colcrys

Mechanism of Interaction Tubulin inhibitor

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBA1A

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBA1B

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB4B

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB

Interaction Types & Directionality:

inhibitor (inhibitory)

binder

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Publications:

Acharya et al., 2009, Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity., Biochemistry

Yee et al., 2005, Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies., Clin. Cancer Res.

Li et al., 2010, Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin., J Mass Spectrom

COLCHICINE TUBB3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBA3D

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBA4A

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBA1C

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE TUBB2B

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE NTF3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

COLCHICINE CYP2C19

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

COLCHICINE GFAP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Mader et al., 2004, Dual mode of signalling of the axotomy reaction: retrograde electric stimulation or block of retrograde transport differently mimic the reaction of motoneurons to nerve transection in the rat brainstem., J. Neurotrauma

Pozas et al., 1999, Fra-1 immunoreactivity in the rat brain during normal postnatal development and after injury in adulthood., Neurosci. Res.

COLCHICINE CYP2D6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Yalcıntepe S et al., 2016, The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients., Eur J Drug Metab Pharmacokinet

COLCHICINE ABCB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics
COLCHICINE CYP1A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
COLCHICINE SCD

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kasturi et al., 1984, Colchicine inhibition of insulin induction of stearoyl-CoA desaturase and fatty acid synthetase in cultured avian liver explants., Arch. Biochem. Biophys.

COLCHICINE IL18

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Antoniou et al., 2004, Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP)., Sarcoidosis Vasc Diffuse Lung Dis

COLCHICINE MAP2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Geddes et al., 1994, Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and MAP2., Brain Res.

COLCHICINE BDNF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

COLCHICINE CYP2B6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.
COLCHICINE SRI

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
COLCHICINE CYP3A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
COLCHICINE CYP2C9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
COLCHICINE ANPEP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Danielsen et al., 1983, Biosynthesis of intestinal microvillar proteins. Role of the Golgi complex and microtubules., Biochem. J.
COLCHICINE SLC2A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Huang et al., 2005, Disruption of microtubules ablates the specificity of insulin signaling to GLUT4 translocation in 3T3-L1 adipocytes., J. Biol. Chem.

COLCHICINE TUBB4A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE RARA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Stromskaya et al., 1998, Influence of exogenous RAR alpha gene on MDR1 expression and P-glycoprotein function in human and rodent cell lines., Br. J. Cancer

Dvorák et al., 2007, Expression, protein stability and transcriptional activity of retinoic acid receptors are affected by microtubules interfering agents and all-trans-retinoic acid in primary rat hepatocytes., Mol. Cell. Endocrinol.

COLCHICINE ITGB2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Cronstein et al., 1995, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils., J. Clin. Invest.

Torre et al., Effects of interleukin-8 on suppression of human lymphocyte polarization and migration by anti-LFA-1 antibody., Eur. Cytokine Netw.

COLCHICINE NRG1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sandrock et al., 1995, ARIA is concentrated in nerve terminals at neuromuscular junctions and at other synapses., J. Neurosci.

COLCHICINE TUBA3C

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Reddy MV et al., 2013, Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents., J Med Chem

Wang F et al., 2015, Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity., Bioorg Med Chem

Zhu C et al., 2014, Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence., J Med Chem

COLCHICINE PIK3CG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lakkakorpi et al., 1997, Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading., Exp. Cell Res.
COLCHICINE TUB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE JUN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE PAX8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE AR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE NFE2L2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE ATAD5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE RORC

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE GMNN

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE CXCL8

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
COLCHICINE CREBBP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB01394

Version: 5.1.7

Alternate Names:

64-86-8 CAS Number

Colchicine Tab 0.6mg Drug Brand

Colchicine Tab 1mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing muscle toxicity

Publications:

Yee et al., 2005, Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies., Clin. Cancer Res.

Dalbeth N et al., 2014, Mechanism of action of colchicine in the treatment of gout., Clin Ther

Finkelstein et al., 2010, Colchicine poisoning: the dark side of an ancient drug., Clin Toxicol (Phila)

TEND: COLCHICINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval approved before 1982

Drug Class gout suppressants

Publications:
TdgClinicalTrial: COLCHICINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of gout

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: COLCHICINE

Version: 02-September-2020

Alternate Names:

CHEMBL107 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Canela MD et al., 2014, Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach., J Med Chem

Minegishi H et al., 2015, Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods., J Med Chem

NCI: COLCHICINE

Version: 14-September-2017

Alternate Names:

C385 NCI drug code

Drug Info:

Publications:

Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

Kasturi et al., 1984, Colchicine inhibition of insulin induction of stearoyl-CoA desaturase and fatty acid synthetase in cultured avian liver explants., Arch. Biochem. Biophys.

Torre et al., Effects of interleukin-8 on suppression of human lymphocyte polarization and migration by anti-LFA-1 antibody., Eur. Cytokine Netw.

PharmGKB: colchicine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics

Yalcıntepe S et al., 2016, The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients., Eur J Drug Metab Pharmacokinet

TTD: Colchicine
- Version: 2020.06.01
Alternate Names:

D09DHY TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL107
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL107
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
GuideToPharmacologyInteractions: 135650118
- Version: 20-July-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Antagonist

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Mechanism of Interaction	Tubulin inhibitor
Direct Interaction	yes

Novel drug target	Established target
Trial Name	colchicine,Colcrys
Mechanism of Interaction	Tubulin inhibitor

64-86-8	CAS Number
Colchicine Tab 0.6mg	Drug Brand
Colchicine Tab 1mg	Drug Brand

COLCHICINE Drug Record

COLCHICINE chembl:CHEMBL107 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Antagonist

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name colchicine,Colcrys Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory) binder

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tubulin inhibitor Direct Interaction yes

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Kasturi et al., 1984, Colchicine inhibition of insulin induction of stearoyl-CoA desaturase and fatty acid synthetase in cultured avian liver explants., Arch. Biochem. Biophys.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Antoniou et al., 2004, Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP)., Sarcoidosis Vasc Diffuse Lung Dis

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Geddes et al., 1994, Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and MAP2., Brain Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name colchicine,Colcrys

Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tubulin inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

binder

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tubulin inhibitor

Direct Interaction yes

Interaction Types & Directionality:

n/a

Publications:

Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Kasturi et al., 1984, Colchicine inhibition of insulin induction of stearoyl-CoA desaturase and fatty acid synthetase in cultured avian liver explants., Arch. Biochem. Biophys.

Interaction Types & Directionality:

n/a

Publications:

Antoniou et al., 2004, Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP)., Sarcoidosis Vasc Diffuse Lung Dis

Interaction Types & Directionality:

n/a

Publications:

Geddes et al., 1994, Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and MAP2., Brain Res.

Interaction Types & Directionality:

n/a

Publications:

Ceccatelli et al., 1991, Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment., Proc. Natl. Acad. Sci. U.S.A.

Interaction Types & Directionality:

n/a

Publications:

Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.

Interaction Types & Directionality:

n/a

Publications:

Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Danielsen et al., 1983, Biosynthesis of intestinal microvillar proteins. Role of the Golgi complex and microtubules., Biochem. J.

Interaction Types & Directionality:

n/a

Publications:

Huang et al., 2005, Disruption of microtubules ablates the specificity of insulin signaling to GLUT4 translocation in 3T3-L1 adipocytes., J. Biol. Chem.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a